Moderna News - January 23, 2026

Moderna Shares Plunge as CEO Halts Funding for New Phase 3 Vaccine Trials

Moderna shares plunged 8.75% to $47.33 after CEO Stéphane Bancel announced the company would not fund new Phase 3 vaccine trials in the foreseeable future,...

🔴 Moderna is trading 3.26% down in pre-market after recent rally pullback

MRNA is trading at $50.18, down 3.26% in pre-market, as the stock experiences profit-taking following a dramatic two-day surge. The initial rally saw the...